Research on new and better ways to treat cancer. Covers radiotherapy, targeted microdroplets, nerve-injury protection, drug combinations, and tumor models.
A study published in Leukemia found that cord blood transplantation (CBT) was more effective than matched related donor transplantation (MRDT) for patients with refractory and relapsed acute myeloid leukemia (R/R AML). The study compared the survival rates of 1,738 CBT-treated patients with those of 713 MRDT-treated patients, revealing...
Researchers discover tBID can induce programmed cell death through mitochondrial damage, revealing a new function for a previously thought signal transducer protein. This finding has implications for treating malignant cells and combating infections like Shigella.
Researchers at Purdue University have identified a new pathway for producing the anti-cancer compound thymohydroquinone, found in plants like thyme and oregano. By understanding this process, plant scientists can engineer plants to produce higher levels of beneficial compounds or synthesize them in microorganisms.
Researchers have discovered that HIV drugs may be effective in treating low-grade brain tumours, specifically meningioma and acoustic neuroma. High levels of HERV-K proteins were found to stimulate the growth of these tumours, and targeted drugs have been identified to reduce their growth.
A novel vaccine, TOH-Vac1, replicates inside the body's cells and generates a powerful immune response in mice and monkeys. The vaccine is based on a strain of vaccinia virus used to vaccinate against smallpox and can be programmed to protect against multiple variants.
A recent study published in JNCCN found that 33 out of 81 studies lacked transparency on censoring, which can introduce bias and affect trial results. The researchers emphasize the need for improved transparency and reporting in clinical trials to ensure patients and clinicians make informed decisions.
Researchers have identified a novel immune-like mechanism by which healthy epithelial cells recognize and eliminate precancerous cells through a MHC class I-LILRB3 interaction. This process generates mechanical force to extrude the precancerous cells from the body, offering new hope for cancer prevention and treatment.
A novel medical cooling system for preventing Chemotherapy-induced peripheral neuropathy (CIPN) is being developed by the University of Huddersfield and Paxman. CIPN causes pain or sensitivity in hands and feet, delaying treatment. The new device uses 'Human Centred Design' to deliver stable cooling, tolerable over chemotherapy duration.
Surgeons at Henry Ford Health performed the world's first precision prostatectomy through the bladder using a single port robotic surgical system. The procedure preserves a portion of the prostate capsule, improving functional outcomes such as erectile function and urinary control.
Researchers have described a dynamic genomic landscape of tumour heterogeneity in hepatocellular carcinoma, highlighting the need for novel strategies targeting heterogeneous tumors. The study, published in National Science Review, used multi-omic data to reveal variations in genetic and transcriptomic profiles across patients.
A recent study found that patients with hormone receptor-positive breast cancer who experience rising ESR1 mutations before disease progression can benefit from an early switch to fulvestrant plus palbociclib. This approach yields a statistically and clinically significant gain in progression-free survival, potentially justifying its a...
Researchers have developed a CRISPR/Cas9 gene editing system to enhance the effectiveness of sonodynamic therapy, allowing tumors to be effectively shrunk in a mouse model of liver cancer. The technology reduces antioxidant defense systems, increasing cancer cell death from the treatment.
A prospective study found that MRI outperformed conventional tests and FDG PET/CT for various staging endpoints in SCLC. Whole-body MRI and FDG PET/MRI were more accurate than FDG PET/CT for assessing local invasion extent.
Researchers have developed smart transformable nanoparticles that can alter their size and shape in response to physiological conditions, improving particle circulation, biodistribution, and targeted therapy for cancer theranostics. These particles promise enhanced tumor diagnoses and treatment by adapting to the physiology of tumors.
Researchers at Hokkaido University analyzed hundreds of women with ovarian granulosa cell tumors to improve understanding of the disease progression and response to therapy. They found that early-stage tumors rarely spread beyond the ovaries, and fertility-sparing surgery may be considered for younger patients.
A research team developed an AI framework that analyzes protein interactions to predict effective and low-toxicity cancer drug combinations. The framework, GraphSynergy, outperforms conventional models in identifying synergistic combinations.
Researchers used next-generation DNA sequencing to detect residual disease in patients treated with CAR-T therapy for acute lymphoblastic leukemia. The study found that DNA sequencing was more sensitive and accurate than flow cytometry in predicting relapse, enabling earlier intervention.
A recent review article describes a class of viruses known as oncolytic viruses, which have the remarkable ability to target and destroy cancer cells. Researchers are exploring these viruses for cancer therapy, with some showing promising results in stimulating an immune response against cancer.
The study evaluated outcomes of minimally invasive esophagectomy compared to open esophagectomy in 6000 ESCC patients over 10 years. MIE was found to be an effective treatment option even for large tumors, expanding its indicated population.
A recent study found that antibiotic resistance rates for Helicobacter pylori are decreasing in European countries. The use of three antibiotics over 10-14 days resulted in success rates of over 90%. The researchers hope to reduce antibiotic consumption to prevent further resistance.
A fasting-mimicking diet was found to be safe and biologically active in cancer patients, with potential benefits for modulation of metabolism and enhancement of antitumor immunity. The study demonstrated significant reductions in blood glucose and growth factor concentrations, as well as enhancements in intratumor T-cell infiltration.
A survey study of 400 parents and 80 clinicians found that nearly one-quarter of parents reported challenges in the therapeutic relationship with their oncologist, highlighting the need for improvement strategies. Clinicians used these strategies more frequently when they experienced relationship difficulties.
A Mount Sinai study reveals that young adult cancer patients exhibit distinct genetic hallmarks and immune system responses compared to their older counterparts. These findings suggest personalized treatment approaches for young adults with various types of cancers.
Researchers aim to reverse tissue damage and scar buildup in lungs affected by Idiopathic Pulmonary Fibrosis (IPF) using a protein domain. The team hopes to identify therapeutic agents that can be used to treat the disease, which affects 100,000 Americans annually.
A study of over 1,100 prostate cancer patients found that androgen deprivation therapy did not increase the risk of death within 30 days after a COVID-19 infection. Researchers concluded that men receiving androgen deprivation therapy had similar mortality rates as those who did not receive this treatment.
A study found that COVID-19 reduced childhood cancer diagnoses by 17%, but increased intensive care admissions before diagnosis.
A new imaging technique called single-shot photoluminescence lifetime imaging thermometry (SPLIT) measures temperature in 2D, without contact, and in real-time. This technology could improve photothermal therapy and help detect skin cancers.
The WVCTSI will deploy a mobile clinical trials unit in West Virginia, addressing health disparities and increasing participation in clinical research. The 39-foot Winnebago will provide on-site clinical trials and follow-up visits to rural residents.
Research reveals that cancer cells have softer membranes than normal cells, but stiffening them can prevent abnormal changes in structure and motility. Stiffened breast cancer cells lost the ability to spread to the lungs in mouse experiments, suggesting a potential strategy for cancer treatments.
A pilot study reveals that whole genome sequencing can refine diagnoses and provide new treatment options for children with cancer. The study found genetic variants that could change prognosis or suggest hereditary causes of the cancers, as well as treatments that may be effective but were not previously considered.
A new pilot study reveals a prostate cancer urine test can identify men with intermediate-risk disease, allowing them to opt for active surveillance instead of immediate treatment. The test assesses the amount of aggressive cancer in the prostate without needing a biopsy.
Researchers at MIT and Harvard University have developed a way to selectively turn on gene therapies in target cells by detecting specific messenger RNA sequences. This technology can fine-tune gene therapies for applications ranging from regenerative medicine to cancer treatment, potentially reducing side effects and increasing efficacy.
Researchers at MD Anderson Cancer Center reported that serial stereotactic body radiation therapy (SBRT) is a safe and effective treatment for oligometastatic renal cell carcinoma. The study showed promising results, with a median progression-free survival of 22.7 months and minimal toxicity.
Scientists at Osaka University developed a novel system for targeted cancer radiation therapy using gold nanoparticles labeled with astatine-211. The nanoparticles are highly toxic to cancer cells while remaining localized, minimizing damage to healthy tissues.
The new ESMO Clinical Practice Guideline provides comprehensive guidance on diagnosing, staging, and treating patients with metastatic breast cancer. The guideline incorporates recent clinical trial data to inform treatment choices, taking into account tumour biology and emerging targeted therapies.
Researchers at the University of Copenhagen have discovered that the BRCA2 gene requires a specific enzyme, PP2A-B56, to repair DNA damage. This finding may pave the way for more targeted treatment of cancer patients with certain mutations.
The study proposes a new approach to inhibit MYC's essential interaction with TRRAP, a protein required for efficient histone acetylation. This disruption could lead to cancer-specific targeted therapies with minimal effects on normal cells.
A survey of breast cancer patients found that nearly half use cannabis to alleviate pain, fatigue, and other symptoms while undergoing treatment. Physicians are often unaware of patients' cannabis use, highlighting the need for informed conversations about its potential benefits and risks.
Researchers found that TAK1-inhibitors NG25 and 5Z-7 reduce the viability of multiple myeloma cell lines and primary cells, inducing apoptosis through various mechanisms. The combination of TAK1 inhibitors with DNA-damaging agents increases cytotoxicity in a synergistic or additive manner.
Researchers at the University of Houston have developed a new, label-free biosensing platform for detecting cancer biomarkers in exosomes. The technology uses gold nanodisks to capture and analyze surface proteins on exosomes with high sensitivity.
A retrospective cohort study of 27 patients with sarcoma lung metastases found high primary technical success rates for percutaneous image-guided microwave and cryoablation. The treatment modality and tumor location did not affect local progression, and smaller tumors showed lower cumulative incidence of local progression.
Researchers developed a gel made of fibrin that improved the effectiveness of CAR-T cell immunotherapy for glioblastoma by enhancing T cell distribution and preventing tumor recurrence. In mouse studies, the gel showed promising results, with 64% of treated mice being tumor-free after 94 days.
Researchers have discovered the molecular mechanisms behind stem cell rolling in blood vessels, a complex process that slows down cells using long tethers. The findings offer new insights into improving stem cell transplantations and developing treatments for metastasizing cancers.
MUSC researcher Haizhen Wang receives R37 grant to investigate CDK6's role in T-cell acute lymphoblastic leukemia, a aggressive cancer. The research aims to understand how the immune system can be used to reduce leukemia progression.
Researchers found that high CD39 expression is associated with human bladder cancer, particularly in the non-muscle-invasive phenotype. CD39's involvement in tumor development and progression is still unclear, but its overexpression in early-stage tumors suggests a potential role in bladder cancer progression.
Researchers developed a fluorescence quenching assay to probe the integrity of cell membrane coating on biomimetic nanoparticles. The study found that only 20% of particles were fully coated, indicating significant limitations in current coating protocols.
The MAP Virtual Congress 2021 focuses on integrating tumour sample analysis into daily practice, enabling personalized treatment. Key findings include actionable mutations in patient DNA and the role of the tumour microenvironment in metastasis.
A new study found that a healthy gut microbiome is essential for skeletal muscles to grow after exercise. Researchers used mice with antibiotics to disrupt the microbiome, showing reduced muscle growth compared to healthy mice. The findings support previous studies linking the gut microbiome to muscle health.
New targeted therapies are being developed to target genetic alterations in cancer cells, such as the ARID1A mutation found in 10-50% of solid tumours. Early clinical trials suggest that these agents may be effective in treating multiple cancers, including breast, ovarian, and gastric cancer.
Researchers identified two subtypes of metastatic prostate cancer that respond differently to hormone treatment. Luminal tumors responded better to testosterone-blocking treatments, while basal tumors did not benefit as much from this hormone treatment.
The VCU Massey Cancer Center has established a Translational Research Center in Lung Cancer Disparities (TRACER) to address racial disparities in lung cancer. TRACER will investigate the interaction between stress, smoking, and gene expression to raise lung cancer risk in Black men.
The report reveals a high risk of preventable cancers among Hispanic/Latino population, with 2-fold higher rates of liver and stomach cancers. Access to quality prevention, early detection, and treatment services is crucial for reducing the cancer burden in this population.
Researchers at Johns Hopkins Medicine have identified promising new targets for pancreatic cancer treatment and early detection, including glycosylated proteins that could be captured in the blood for diagnosis. The study also suggests new ways to improve immune response to these tumors.
Researchers at St. Jude Children's Research Hospital found that the tumor suppressor gene PTEN controls rhabdomyosarcoma cell identity and that enhancing PAX7 expression can maintain tumor cell existence, providing a potential treatment target for rhabdomyosarcoma.
Researchers at the University of Basel have discovered a novel combination therapy approach that combines inhibiting JAK2 with targeting the MAPK signaling pathway. This dual targeting strategy has shown promising results in improving leukemia treatment outcomes by reducing blood cell production and altering disease course.
Researchers develop a novel cell reprogramming strategy to transform glioma cells into non-proliferative neurons. This approach shows promise in slowing down the growth of GBMs and overcoming harmful side effects of conventional treatments.
Researchers at Max-Planck-Gesellschaft engineered synthetic exosomes that regulate cellular signaling during wound closure, leading to faster healing and improved formation of new blood vessels. The study provides a systematic understanding of extracellular vesicle communication and its potential therapeutic application.
Researchers identified DNA mutations from platinum-based chemotherapies in AML patients, suggesting treatment-associated cancer development. The study's findings imply that clonal hematopoiesis precedes chemotherapy exposure.
Recent study by Okayama University researchers reveals three photoinitiators cause faster increase in breast tumor growth in mice, with tamoxifen pretreatment reducing toxicity. The findings suggest photoinitiators could act as hormonal disruptions, raising concerns for patients and healthy individuals.
Researchers at USC Viterbi School of Engineering have discovered a way to boost the effectiveness of CAR T-cell therapy for treating solid tumors, including breast and melanoma. By engineering CAR T-cells to produce an enzyme called adenosine deaminase, they break down an immune-suppressive microenvironment, allowing cancer-killing cel...